Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A new treatment option may be on the horizon for thyroid eye disease. Early phase 3 data from two trials show that satralizumab, an IL-6 receptor-targeting antibody, significantly reduced eye bulging and inflammation compared to placebo. One trial hit statistical significance on the primary endpoint, and both showed meaningful improvements in inflammation scores.
Satralizumab, an antibody that targets the interleukin-6 (IL-6) receptor, is showing early promise for patients with thyroid eye disease (TED) — a condition that can cause painful eye bulging, inflammation, and double vision. Interim 24-week results from two ongoing phase 3 trials (SatraGO-1 and SatraGO-2) found that the drug outperformed placebo across multiple measures, with a strong safety profile and no serious infections reported in the treatment arms.
The trials enrolled over 250 adults with active, moderate-to-severe or inactive TED across 85 sites worldwide. Patients received subcutaneous satralizumab or placebo every 4 weeks after loading doses.
Why it matters: With limited approved therapies for TED, satralizumab's IL-6 pathway inhibition could represent a meaningful new treatment paradigm — especially for patients who haven't responded well to existing options.
